Why is an antipsychotic used as an antidepressant?

Amisulpride's effect is dose-dependent. At low doses (around 50 mg) it mainly blocks the presynaptic autoreceptors that restrain dopamine release, so dopaminergic signaling rises and produces a mood-lifting, activating effect. At higher doses it blocks postsynaptic receptors and acts as an antipsychotic.

Is it more effective than SSRIs for depression?

In randomized trials amisulpride 50 mg was comparable to SSRIs such as fluoxetine, paroxetine and sertraline in dysthymia and mild chronic depression, with a faster early response in some studies. It is not universally superior and is not a first-line antidepressant.

Is it available over the counter?

No. Amisulpride is a prescription medicine, not a dietary supplement or over-the-counter nootropic. It is licensed in Europe but must be used under medical supervision because of prolactin, cardiac and movement-related risks.

ApprovedFDA approvedStrong evidence

Amisulpride

Name: Amisulpride
Creator: MolekulaX

Benzamide atypical antipsychotic; at low doses a dopaminergic antidepressant.

AntidepressantDopaminergicAntidepressantMoodDopamineSerotonin

Available at

PCTZONE-10% coupon: MOLEKULAX

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassAntidepressant · Mood

Primary targetPresynaptic dopamine D2 autoreceptor antagonism

Targets3 receptor targets

Half-lifeAbout 12 hours; excreted largely unchanged via the kidneys

OnsetAntidepressant effect at low dose often within 1-2 weeks

EvidenceStrong evidence

Affected systemsDopamineSerotonin

Contents

WHAT IS AMISULPRIDE?

Detailed overview

Amisulpride is a substituted benzamide, a prescription atypical antipsychotic that strongly and selectively blocks dopamine D2 and D3 receptors and is also a potent 5-HT7 serotonin receptor antagonist. Its action is strikingly dose-dependent: at low doses (around 50 mg) it preferentially blocks the presynaptic autoreceptors that restrain dopamine release, increasing dopaminergic signaling and producing an antidepressant, activating effect, whereas at high doses it blocks postsynaptic receptors for an antipsychotic effect. Several randomized controlled trials have shown efficacy in dysthymia and chronic mild depression, where it matched or responded faster than SSRIs. It is a widely licensed medicine in Europe (as Solian and Deniban); its oral form is not approved in the United States.

Mechanism

D2/D3 antagonist + 5-HT7 antagonist (dose-dependent)

Half-life

About 12 hours (renally cleared)

Legal status

Prescription (licensed in the EU)

Receptor profile

Dopamine D2 receptor (presynaptic autoreceptor)Strong
Dopamine D3 receptorStrong
5-HT7 serotonin receptor (antagonist)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

Hyperprolactinemia: raised prolactin causing galactorrhea, amenorrhea, sexual dysfunction and reduced libido
Extrapyramidal symptoms at higher (antipsychotic) doses: tremor, rigidity, akathisia
Insomnia, anxiety or restlessness, especially with low-dose activating use
Weight gain and metabolic changes with prolonged use
QT-interval prolongation on ECG, with dose-dependent cardiac rhythm risk
Gastrointestinal complaints: nausea, constipation, dry mouth

Contraindications · 6

Contraindicated in prolactin-dependent tumors (e.g. breast cancer, pituitary prolactinoma)
Pheochromocytoma: disturbing catecholaminergic balance can be dangerous
Renal impairment: the drug is cleared mainly by the kidneys and can accumulate
Congenital long-QT syndrome or combination with other QT-prolonging drugs
Pregnancy and breastfeeding: safety not established, only after medical assessment
Parkinson's disease: dopamine antagonism can worsen motor symptoms

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

J Affect Disord. 1997

Amisulpride versus imipramine and placebo in dysthymia and major depression

Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O

PMID: 9165379Open

J Affect Disord. 1999

Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study

Ravizza L

PMID: 9495601Open

Neuropsychobiology. 1999

Amisulpride versus amineptine and placebo for the treatment of dysthymia

Boyer P, Montgomery S, Lepola U, et al.

PMID: 9892856Open

Int Clin Psychopharmacol. 2001

Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study

Amore M, Jori MC

PMID: 11712619Open

Int Clin Psychopharmacol. 2002

Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study

Cassano GB, Jori MC

PMID: 11800503Open

Psychopharmacology (Berl). 2009

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL

PMID: 19337725Open

FAQ

Benzamide atypical antipsychotic; at low doses a dopaminergic antidepressant.

Have a question about Amisulpride?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeAntidepressant

FormulaC17H27N3O4S

UpdatedJuly 10, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.